Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Non-Current Deffered Revenue (2023 - 2025)

Metagenomi (MGX) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 70.8% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 70.8% year-over-year, with the annual reading at $3.0 million for FY2025, 70.8% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $3.0 million at Metagenomi, up from $1.9 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $30.9 million in Q4 2023, with the low at $1.9 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 3 years is $11.6 million, with a median of $10.2 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 66.9% in 2024, then plummeted 84.75% in 2025.
  • Over 3 years, Non-Current Deffered Revenue stood at $30.9 million in 2023, then tumbled by 66.9% to $10.2 million in 2024, then tumbled by 70.8% to $3.0 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $3.0 million, $1.9 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.